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Defects in which the conal septum is rotated 
out of the remainder of the muscular ventricu‑
lar septum are called malalignment VSDs. Spo‑
radically, a specific type of VSD in the mem‑
branous part of the ventricular septum (above 
the tricuspid valve) may occur, causing a direct 
shunt from the left ventricle to the right atri‑
um, named Gerbode defect. Despite the location, 
VSDs vary in size, which determines the clini‑
cal course and management of the disease. Even 
small VSDs may require treatment due to unfa‑
vorable position (eg, subaortic).
Currently, open heart surgery remains the 
treatment of choice for symptomatic VSDs. How‑
ever, a standard transatrial or transarterial 
IntroductIon Ventricular septal defect 
(VSD) is one of the most common (41.6%) con‑
genital heart defects.1 It may occur as a solitary 
defect, multiple openings, or part of complex 
cardiovascular malformations. Considering VSD 
borders, the condition can be classified as peri‑
membranous (pmVSD; 75%), muscular (mVSD; 
20%), or subarterial (about 5%).1 Among mVSDs, 
there are trabecular defects located in the ante‑
rior, mid, posterior, or apical part of the ventric‑
ular septum. Posterior mVSD differs from peri‑
membranous inlet VSD (so ‑called atrioventricu‑
lar canal–type defect) by the presence of a supe‑
rior muscular rim just below the septal leaflet of 



















Background Ventricular septal defect (VSD) is one of the most common congenital heart defects. 
Currently, surgery remains the treatment of choice. However, transcatheter techniques for closing of 
various types of VSDs have become an alternative.
aims The objective of our study was to present the outcomes of transcatheter closure of various types 
of VSD based on a systematic review of recent publications.
methods A systematic review of studies published in English between January 2014 and March 2020 
was performed using the PubMed database (MEDLINE) independently by 2 reviewers. Data on success 
and complication rates were extracted. Studies including fewer than 5 patients and those with acquired 
VSD were excluded from the analysis.
results Finally, 44 studies were included for analysis, with a total number of 4050 patients. The pooled 
estimate of the overall success rate based on the random effects model was 97.96% (95% CI, 97.37–98.56; 
Q test P <0.001; I2 = 50%). Early residual shunt was the most common complication with a pooled estimate 
rate of 22.25% (95% CI, 16.46–28.05; P <0.001; I2 = 95%). However, only 92 patients had permanent VSD. 
Complete atrioventricular block constituted the most dangerous complication, and the pooled estimate 
rates were assessed as 0.64% (95% CI, 0.39–0.88; I2 = 0%) for transient VSD and 0.32% (95% CI, 0.15–0.49; 
P >0.99; I2 = 0%) for permanent VSD.
conclusions Transcatheter closure of selected VSDs appears to be an effective and safe method of treatment. 
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included. We excluded single ‑case studies, se‑
ries of cases of fewer than 5 patients, and stud‑
ies on acquired post–myocardial infarction or 
posttraumatic VSD. Studies without follow ‑up 
or with a significant lack of data were also ex‑
cluded. To avoid potential duplicate or overlap‑
ping results, the list of all studies selected in 
the first step were reviewed by the 2 previously 
mentioned authors and another one so far not in‑
volved in study selection. In that step, 3 duplicat‑
ed studies were found and excluded. The whole 
detailed process used for study screening and 
selection is illustrated in the PRISMA flow dia‑
gram (Supplementary material, Figure S1).5 Fi‑
nally, out of 312 studies found, 44 were final‑
ly considered for analysis. Further information 
about the type of VSD, devices used, patients’ 
age, follow ‑up, success rates, as well as types 
and frequency of complications was extracted 
by one of the authors and entered into an elec‑
tronic database. Successful implantation was de‑
fined as correct and stable placement with sat‑
isfactory effects confirmed by imaging. The suc‑
cess rate was obtained from the articles that fea‑
tured this information or otherwise calculated. 
Of valvular lesions, only a new onset of aortic or 
tricuspid regurgitation was considered. Compli‑
cations were regarded as permanent if they re‑
mained present at the time of the latest follow‑
‑up. A complication was considered early if it 
appeared during procedure ‑related hospitaliza‑
tion. The approval of an ethical committee was 
waived because of the study design (a review of 
published studies).
statistical analysis To address the possi‑
bility of publication bias, a funnel plot of sam‑
ple size was generated against the success rate 
of each study. The random effect model and 
the empirical Bayes method were used to ob‑
tain pooled estimates of rates of success and 
various types of complications.6,7 It was pos‑
tulated that the 44 studies represented a ran‑
dom sample from the larger population of such 
studies, with each study having its own under‑
lying effect size. This model assumes that there 
is a mean population effect size with regard to 
which study ‑specific effect varies. Heterogeneity 
among studies was evaluated using the inconsis‑
tency statistic. A 2‑sided proportion test from 
the OpenMetaAnalyst software was used for 
statistical analysis.7 For all tests, a P value less 
than 0.05 was considered significant. The fun‑
nel plot was created using the MedCalc soft‑
ware, version 19.3.1 (MedCalc Software, Ltd., 
Ostend, Belgium).
results Finally, 44 studies8‑51 were analyzed, 
with a total number of 4050 patients (Supple‑
mentary material, Table S2). The years 2018 and 
2019 prevailed in the number of publications 
surgical approach may be problematic in some 
cases. This particularly applies to VSDs in which 
it is difficult to obtain surgical access and exten‑
sive ventriculotomy or postoperational residual 
shunts (RSs) are required. Previous reports on 
the outcomes of surgical VSD treatment have 
shown a significant risk of RS, early and late car‑
diac arrhythmias, conduction disturbances, pro‑
longed hospitalization time, as well as increased 
hospital morbidity and mortality ranging be‑
tween 1.4% and 2.17%.2 In addition, a negative 
psychological impact of surgical trauma and scars 
should be considered. For this reason, transcath‑
eter techniques for closing of various types of 
VSDs have become a helpful alternative, which 
allows us to avoid or supplement the operation. 
Risks associated with this treatment method in‑
clude: device migration or embolism, aortic or tri‑
cuspid valve regurgitation, hemolysis, transient 
ischemic stroke, cardiac arrhythmia, rarely com‑
plete atrioventricular block (CAVB), and intraven‑
tricular conduction disturbances.3,4
Since the first percutaneous transcatheter clo‑
sure of VSD was performed, technical advanc‑
es and the number of various types of occlud‑
ers along with experience in their use have sig‑
nificantly increased.1 Based on a systematic re‑
view of recent publications, we aimed to present 
the outcomes of transcatheter closure of various 
types of VSD. Such analysis could be helpful in 
everyday practice of a wide range of clinicians.
Methods A systematic review of studies pub‑
lished in English between January 2014 and 
March 2020 was performed using the PubMed 
database (MEDLINE) with the following terms 
searched: “transcatheter ventricular septal de‑
fect closure,” “interventional septal defect clo‑
sure,” and “ventricular septal defect.” From this 
search list, studies that fulfilled the predeter‑
mined criteria were selected independently by 
2 reviewers and entered into an electronic da‑
tabase. Prospective and retrospective (random‑
ized and nonrandomized) studies reporting data 
on transcatheter closure of any type of congeni‑
tal VSD, using any type of device, and with well‑
‑defined follow ‑up (based on electrocardiograph‑
ic and echocardiographic assessments) were 
whAt’s new?
Our review summarized recent outcomes of transcatheter closure of various 
types of ventricular septal defects reported in the literature between January 
2014 and March 2020. To our best knowledge, the last similar review was 
published in 2017. Since then, a significant number of relevant papers has 
been published. Unlike in previous reviews, we classified the incidence of 
complete atrioventricular block as transient or chronic, considering a notably 
different clinical significance of both types. Our study showed high rates of 
successful interventions with an acceptable incidence of complications. This 
is the first such analysis in the Polish medical literature.
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cases of intracristal VSD, 24 of doubly commit‑
ted VSD, and 14 of Gerbode defect, among oth‑
ers). The median duration of follow ‑up ranged 
from 6.5 to 110 months (Supplementary mate‑
rial, Table S2).14,41 A total of 40 out of 44 studies 
(90.91%) reported a success rate exceeding 90%. 
To assess the risk of publication bias, a funnel 
plot was constructed (FIgUre 2) without any obvi‑
ous funnel asymmetry. The pooled estimate of 
the overall success rate based on the random ef‑
fects model was 97.96% (95% CI, 97.37–98.56; 
FIgUre 3). However, the Q statistic showed a sig‑
nificant heterogeneity (P <0.001; I2 = 50%) for 
that result.
Early residual shunt, reported in 640 cas‑
es (15.8%) in 39 studies, constituted the most 
common complication. Its pooled estimate 
rate was 22.25% (95% CI, 16.46–28.05; Q test 
P <0.001; I2 = 95%; FIgUre 4). However, only 92 re‑
sidual shunts (in 29 studies) were present at the 
last follow ‑up visit and regarded as perma‑
nent, with a pooled estimate rate of 2.11% (95% 
CI, 1.24–2.97; Q test P <0.001; I2 = 52%). In 15 
studies, no residual shunt was found at the last 
follow ‑up visit. In well ‑documented control stud‑
ies, Haas et al35 showed that complete VSD clo‑
sure occurred in 90 of 101 patients at 3 months, 
93 of 98 at 6 months, 94 of 97 at 12 months, 82 
of 83 at 18 months, 67 of 68 at 24 months, 31 
of 31 at 36 months, and 16 of 16 at 48 months. 
The highest documented rate of permanent re‑
sidual shunt was 23.08%.24
Next, the occurrence of CAVB was assessed. 
In this review, in most cases, CAVB was tran‑
sient, with an incidence of 35 events in 21 stud‑
ies. Its pooled estimate rate was 0.64% (95% CI, 
0.39–0.88; Q test P >0.99; I2 = 0%; FIgUre 5). Accord‑
ing to reported data, CAVB resolved in 10 cases 
(28.57%) after steroid‑only treatment. Howev‑
er, there were 12 cases (in 8 studies) of perma‑
nent CAVB with a pooled estimate rate of 0.32% 
(95% CI, 0.15–0.49; Q test P >0.99; I2 = 0%; FIgUre 6). 
The highest reported incidence of this complica‑
tion was 8.33% (a single patient among 12 indi‑
viduals).28 An interesting case was described by 
Haddad et al,14 wherein CAVB occurred imme‑
diately after the device was released, but sinus 
rhythm returned 5 minutes after intravenous 
bolus administration of atropine and steroids. It 
was classified as transient, and the patient was 
discharged in a good condition. After 18 months, 
the presence of CAVB was again revealed during 
a routine follow ‑up visit and the patient required 
permanent pacemaker implantation.
The postprocedural occurrence of tricuspid and 
aortic valve regurgitation is summarized in TAble 1. 
The highest reported incidence of early tricus‑
pid valve regurgitation was 25.49% (26 of 102 pa‑
tients).29 However, it was 40.91% (9 of 22 patients) 
for aortic valve regurgitation.18 A review of reports 
showed a decrease in the incidence of these lesions 
over time, more frequently involving the tricuspid 
(10 each year; 22.73%) (Supplementary mate‑
rial, Table S2). Types of devices used in stud‑
ies through the analyzed years are presented in 
FIgUre 1. The Amplatzer Duct Occluder (ADO) was 
one of the most commonly used instruments (in 
24 studies; FIgUre 1). Most studies included pediat‑
ric populations with a small proportion of adults, 
at age ranging between 13 days to 65.6 years.33,39 
Narin et al28 reported 12 cases of successful in‑
tervention in the population under 1 year of age 
(range, 2–12 months). Moreover, Pillai et al17 con‑
ducted a study in a group of 49 children weigh‑
ing up to 10 kg, at a median (interquartile range) 
age of 18 (13–22) months. Perimembranous VSD 
was the most common type of defect observed 
(3812 patients in 38 out of 45 studies). Muscular 
VSD was described in 66 cases (8 studies), post‑
operative or residual VSD, in 41 cases (7 stud‑
ies), and 131 patients had other types of VSD (85 
 Figure 1 Devices used in each analyzed year
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Figure 2 Funnel plot of interventional success rates
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dIscussIon Cardiac surgery has had an estab‑
lished position in the treatment of VSD for years, 
and, in some VSD types, it represents the treat‑
ment of choice. However, according to the newest 
2020 European Society of Cardiology guidelines, 
transcatheter VSD closure has become an alter‑
native, particularly in residual VSDs, VSDs poor‑
ly accessible by surgery, and in mVSDs located 
centrally in the interventricular septum.52 It has 
also been deemed feasible in pmVSD.52 Moreover, 
this procedure has significant advantages such as 
shorter hospitalization, faster recovery time, pos‑
sibility to avoid cardiopulmonary bypass, lower 
incidence rates for some complications compared 
with surgery, and weaker psychological impact.53 
valve. The pooled estimate rate for mild or lower tri‑
cuspid valve regurgitation in the last follow ‑up pe‑
riod was 1.92% (95% CI, 0.91–2.94; Q test P <0.001; 
I2 = 52%), and 1.15% for aortic valve regurgitation 
(95% CI, 0.47–1.82; Q test P = 0.03; I2 = 30%).
Hemolysis occurred in 39 cases document‑
ed in 10 reports. Most of them were described 
as mild and transient, but 6 cases required 
early surgical intervention. The pooled esti‑
mate rate for its incidence was 0.52% (95% CI, 
0.29–0.74; Q test P = 0.65; I2 = 0%). In the study 
with the highest rate, 8 cases of hemolysis oc‑
curred in the periprocedural period (4 were 
transient and self ‑limiting and 4 required 
blood transfusion).11
Figure 3 Forrest plot of interventional success rates
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of not only the success rate but also safety of 
the procedure. The high pooled estimate of 
the overall success rate of implantation (97.96%; 
95% CI, 97.37–98.56) in our review suggests 
that most devices have been successfully de‑
ployed with good outcomes leading to VSD clo‑
sure. Similar results were reported in analyses 
conducted by Santhanam et al3 (97.8%; 95% 
CI, 96.8–98.6) and Yang et al4 (96.6%; 95% CI, 
95.7–97.5). These results may also suggest a cer‑
tain increase in the effectiveness of the meth‑
od over the years. Failures were mainly associ‑
ated with large RSs, instability of selected de‑
vices, or serious complications such as CAVB 
or embolization.8‑51
On the other hand, complications of percutaneous 
VSD closure, such as various cardiac arrhythmias 
and CAVB, valvular disease, excessive bleeding, 
embolic risk, injury to the manipulated blood ves‑
sels, and hematoma formation in the groin, can 
be resolved.3,4 Therefore, the use of transcatheter 
versus surgical procedures still requires weighing 
risks and benefits associated with each method, 
considering the type and size of VSD, patients’ age 
and weight, available equipment, and experience 
of the catheterization laboratory team.
In this systematic review, we attempted to 
evaluate whether transcatheter closure of the 
selected types of VSD in pediatric patients is 
an effective method of treatment, in terms 
study estimated occurrence 
(95% ci)
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 Figure 4 Forrest plot of early residual shunt occurrence
 Abbreviations: see FIgUre 3
KARDIOLOGIA POLSKA 2021; 79 (2)166
unacceptable incidence (3.8%) of this danger‑
ous complication.53 The 2007 European regis‑
try of transcatheter closure of congenital VSDs 
showed an occurrence rate for CAVB of 5% after 
pmVSD closure and 0.8% after mVSD closure, 
and for residual post ‑surgery VSD, at 6.7%. In 
addition, in 6 cases, CAVB was transient, while 
in 10 (3.8%; early in 6, and late in 4), a pace‑
maker was necessary.54 This raised many con‑
cerns related to interventional treatment. In 
our analysis, CAVB was reported in 23 studies 
with a total of 47 cases (1.16% of all patients). 
Unlike previous studies, the incidence of CAVB 
in our analysis was classified as transient and 
The presence of RS was the most common com‑
plication related to intervention in our review, 
and other available analyses provided similar ob‑
servations.3,4 Yang et al4 reported findings sim‑
ilar to ours, with the pooled incidence rates of 
early RS at 25.5% (95% CI, 18.9–32.1) and per‑
manent RS at 3.1% (95% CI, 2–4.1). However, 
the corresponding rates in the analysis of San‑
thanam et al3 were lower: 15.9% (95% CI, 10.9–
21.5) for early RS, and 1.7% (95% CI, 0.8–2.7) 
for permanent RS.
Permanent CAVB was the most serious com‑
plication associated with transcatheter VSD 
closure. Previous studies have suggested a high, 
study estimated occurrence 
(95% ci)
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 Figure 5 Forrest plot of transient complete atrioventricular block occurrence
 Abbreviations: see FIgUre 3
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chronic. The reason for such categorization was 
the fact that chronic CAVB requiring pacemak‑
er implantation is the clinically most serious 
condition. Also, most CAVBs in the reviewed 
studies were transient and often showed a good 
response to steroids. Other cases were resolved 
by surgical removal of the device and VSD clo‑
sure. The pooled estimate rate for transient 
CAVB was 0.64% (95% CI, 0.39–0.88), and for 
permanent CAVB, 0.32% (95% CI, 0.15–0.49). 
Santhanam et al3 noted CAVB in 120 patients 
(33 required pacemaker implantation) out of 
a total of 6762 patients, with the pooled in‑
cidence rate of 1.1%. In another systematic 
study estimated occurrence 
(95% ci)
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 Figure 6 Forrest plot of permanent complete atrioventricular block occurrence
 Abbreviations: see FIgUre 3
Table 1 Presence of new ‑onset valvular lesions






Mild or less severe 76 (1.88); 10 74 (1.83); 12
At least moderate 9 (0.22); 5 1 (0.02); 1
Aortic valve 
regurgitation
Mild or less severe 53 (1.31); 16 48 (1.19); 16
At least moderate 16 (0.4); 9 1 (0.02); 1
Data are presented as number of patients (percentage of all participants included in the review); 
number of studies reporting event occurrence.
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review, Yang et al4 described 107 cases of CAVB 
in a population of 4406 patients, and 36 of 
the patients needed a pacemaker. Moreover, 
the authors estimated the overall pooled inci‑
dence rate of CAVB at 2.4% (95% CI, 1.6–3.2). 
Numerous cases of resolved CAVB by the end 
of the follow ‑up period suggest that the reason 
for it is, at least in part, related to transient in‑
flammation or edema at the site of device place‑
ment. The successful use of anti ‑inflammatory 
agents, such as steroids, in those cases further 
supports this hypothesis.4
Haas et al35 suggested that a specific spiral 
type of occluders, such as the NitOcclud Lê VSD 
coils, may pose a lower risk of causing CAVB 
(no case of permanent CAVB among 111 pa‑
tients). What is more, this complication was 
not observed in the study by Houeijeh et al,11 in 
which the same devices were used. Due to dif‑
ficulty in classifying the observed valvular le‑
sions, data should be interpreted with caution. 
Very low incidence rates of tricuspid or aor‑
tic valve regurgitation are associated with re‑
strictive criteria. However, the data on general 
permanent valvular disease presented by San‑
thanam et al3 did not differ significantly from 
ours, and the overall incidence reported was 
1.3% (95% CI, 0.6–2.3).
study limitations The  generally variable 
quality of data reporting in the included stud‑
ies made it difficult to assess their methodolog‑
ical quality and thereby judge their risk of bias. 
Regardless of our best efforts, as in all meta‑
‑analyses, inherent gaps in data presentation in 
individual studies constituted a limitation. Dif‑
ficulties were encountered when classifying suc‑
cess and complication rates, as descriptions in 
articles were not always clear. Not every patient 
included in the review completed the planned 
follow ‑up. A large amount of data made the anal‑
ysis challenging. Moreover, the study protocol 
was not registered. These limitations should be 
considered when making conclusions and estab‑
lishing hypotheses for future research.
conclusions Our review demonstrated that 
transcatheter closure of selected VSDs seems 
to be an effective and safe method of treatment. 
Recent studies have shown high rates of success‑
ful interventions with an acceptable incidence of 
complications. However, some dangerous events 
(eg, CAVB) are still possible. In this review, we 
attempted to summarize the latest (January 
2014 to March 2020) data in the field of VSD in‑
terventional treatment. Admittedly, there are 
only a few analyses similar to ours and further 
research in the field is needed.
supplementary material
Supplementary material is available at www.mp.pl/kardiologiapolska.
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